வீதித் ஷர்மா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வீதித் ஷர்மா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வீதித் ஷர்மா Today - Breaking & Trending Today

Second look analysing prostate cancer study data reaps new rewards


Dr Maha Hussain at the recent virtual ASCO Meeting. Credit: ASCO
Second look analysing prostate cancer study data reaps new rewards
Two studies unveiled at last month’s virtual Genitourinary Cancers Symposium, organised by the American Society of Clinical Oncology, will have implications for both the treatment of prostate cancer and the provision of screening,
Peter Doyle reports
In men with non-metastatic castration-resistant prostate cancer (nmCRPC) and rapidly rising prostate specific antigen (PSA) treated with androgen deprivation therapy (ADT) plus enzalutamide (ENZA), there was a close relationship between the degree of PSA decline and survival outcomes, according to a newly published post-hoc analysis of the PROSPER trial. ....

United States , Maha Ha Hussain , Vidit Sharma , Robert Dreicer , Peter Doyle , Us Preventive Services Task Force , University Of California Los Angeles , American Society Of Clinical Oncology , American Association Of Central Cancer Registries , Genitourinary Cancers Symposium , American Society , Clinical Oncology , Efficacy Study , Services Task Force , North American Association , Central Cancer Registries , Behavioral Risk Factor Surveillance System , California Los , ஒன்றுபட்டது மாநிலங்களில் , மஹா எச்ஏ ஹுசைன் , வீதித் ஷர்மா , ராபர்ட் திரேசெர் , பீட்டர் டாய்ல் , எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி படை , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா லாஸ் ஏஞ்சல்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,

ASCO GU 2021: Association of Reductions in PSA Screening Across States with Increased Metastatic Prostate Cancer in the United States


SHARE
ASCO GU 2021: Association of Reductions in PSA Screening Across States with Increased Metastatic Prostate Cancer in the United States
Published 13 February 2021
(UroToday.com) Prostate cancer screening using prostate-specific antigen (PSA) testing has been controversial since shortly after its introduction in large part due to concerns of over-diagnosis and over-treatment, with the associated morbidity. Thus, despite improvements in prostate cancer-related metastasis and mortality demonstrated in the European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized trial from Europe, PSA screening has remained contentious. In both 2008 and 2012, the US Preventive Services Task Force (USPSTF) did not recommend PSA screening. Some have attributed increased rates of metastatic prostate cancer in the US to reductions in PSA screening as a result of these recommendations from the USPSTF. To test this hypothesis, in the Poster Highlights: Prostate Cancer ....

United States , Vanderbilt University , Christopher Jd Wallis , Vidit Sharma , Us Preventive Services Task Force , Vanderbilt University Medical Center , American Society Of Clinical Oncology , American Association Of Central Cancer Registries , European Randomized Study , Prostate Cancer , Services Task Force , Poster Highlights , Disease Session , Clinical Oncology , Cancers Symposium , North American Association , Central Cancer Registries , Behavioral Risk Factor Surveillance System , Mayo Clinic , Urologic Oncology Fellow , ஒன்றுபட்டது மாநிலங்களில் , வாண்டர்பில்ட் பல்கலைக்கழகம் , கிறிஸ்டோபர் ஜ்ட் வாலிஸ் , வீதித் ஷர்மா , எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி படை , வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம் ,

Drop in PSA Screening, Increase in Metastatic Prostate Cancers